{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:27:00Z","timestamp":1783945620677,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T32 DK 07760"],"award-info":[{"award-number":["T32 DK 07760"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23 DK119584"],"award-info":[{"award-number":["K23 DK119584"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["MSSS\/FRQS Phase 2 Award"],"award-info":[{"award-number":["MSSS\/FRQS Phase 2 Award"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10620-020-06454-5","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T04:52:55Z","timestamp":1594443175000},"page":"1989-1997","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Enteric-Release Budesonide May Be Useful in the Management of Non-Responsive Celiac Disease"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-8598","authenticated-orcid":false,"given":"Amelie","family":"Therrien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn A.","family":"Silvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen M.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Leffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran P.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"key":"6454_CR1","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1016\/j.cgh.2018.03.016","volume":"16","author":"P Singh","year":"2018","unstructured":"Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:e822.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6454_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/ajcn\/79.4.669","volume":"79","author":"JA Murray","year":"2004","unstructured":"Murray JA, Watson T, Clearman B, Mitros F. Effect of a gluten-free diet on gastrointestinal symptoms in celiac disease. Am J Clin Nutr. 2004;79:669\u2013673.","journal-title":"Am J Clin Nutr"},{"key":"6454_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.cgh.2006.12.006","volume":"5","author":"DA Leffler","year":"2007","unstructured":"Leffler DA, Dennis M, Hyett B, Kelly E, Schuppan D, Kelly CP. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol. 2007;5:445\u2013450.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6454_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ajcn\/85.1.160","volume":"85","author":"C Catassi","year":"2007","unstructured":"Catassi C, Fabiani E, Iacono G, et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr. 2007;85:160\u2013166.","journal-title":"Am J Clin Nutr."},{"key":"6454_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-230X-13-40","volume":"13","author":"JR Hollon","year":"2013","unstructured":"Hollon JR, Cureton PA, Martin ML, Puppa EL, Fasano A. Trace gluten contamination may play a role in mucosal and clinical recovery in a subgroup of diet-adherent non-responsive celiac disease patients. BMC Gastroenterol. 2013;13:40.","journal-title":"BMC Gastroenterol"},{"key":"6454_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrgastro.2015.155","volume":"12","author":"T van Gils","year":"2015","unstructured":"van Gils T, Nijeboer P, van Wanrooij RL, Bouma G, Mulder CJ. Mechanisms and management of refractory coeliac disease. Nat Rev Gastroenterol Hepatol. 2015;12:572\u2013579.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"6454_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.cgh.2010.04.009","volume":"8","author":"S Jamma","year":"2010","unstructured":"Jamma S, Rubio-Tapia A, Kelly CP, et al. Celiac crisis is a rare but serious complication of celiac disease in adults. Clin Gastroenterol Hepatol. 2010;8:587\u2013590.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6454_CR8","doi-asserted-by":"crossref","unstructured":"Therrien A, Silvester JA, Leffler DA, Kelly CP. Efficacy of enteric-release oral budesonide in treatment of acute reactions to gluten in patients with celiac disease. Clin Gastroenterol Hepatol. 2020;18:254\u2013256.","DOI":"10.1016\/j.cgh.2019.03.029"},{"key":"6454_CR9","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1111\/j.1572-0241.2007.01380.x","volume":"102","author":"P Brar","year":"2007","unstructured":"Brar P, Lee S, Lewis S, Egbuna I, Bhagat G, Green PH. Budesonide in the treatment of refractory celiac disease. Am J Gastroenterol. 2007;102:2265\u20132269.","journal-title":"Am J Gastroenterol"},{"key":"6454_CR10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/ajg.2017.71","volume":"112","author":"SS Mukewar","year":"2017","unstructured":"Mukewar SS, Sharma A, Rubio-Tapia A, Wu TT, Jabri B, Murray JA. Open-capsule budesonide for refractory celiac disease. Am J Gastroenterol. 2017;112:959\u2013967.","journal-title":"Am J Gastroenterol"},{"key":"6454_CR11","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/j.1440-1681.2009.05211.x","volume":"36","author":"C Ciacci","year":"2009","unstructured":"Ciacci C, Maiuri L, Russo I, et al. Efficacy of budesonide therapy in the early phase of treatment of adult coeliac disease patients with malabsorption: an in vivo\/in vitro pilot study. Clin Exp Pharmacol Physiol. 2009;36:1170\u20131176.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"6454_CR12","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/nu9101129","volume":"9","author":"MM Leonard","year":"2017","unstructured":"Leonard MM, Cureton P, Fasano A. Indications and use of the gluten contamination elimination diet for patients with non-responsive celiac disease. Nutrients. 2017;9:1129.","journal-title":"Nutrients"},{"key":"6454_CR13","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/ajg.2013.79","volume":"108","author":"A Rubio-Tapia","year":"2013","unstructured":"Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. American College of Gastroenterology clinical guideline: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108:656\u2013676.","journal-title":"Am J Gastroenterol"},{"key":"6454_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/MCG.0b013e3181f42401","volume":"45","author":"S Jamma","year":"2011","unstructured":"Jamma S, Leffler DA, Dennis M, et al. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol. 2011;45:30\u201333.","journal-title":"J Clin Gastroenterol"},{"key":"6454_CR15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1053\/j.gastro.2018.12.010","volume":"156","author":"S Husby","year":"2019","unstructured":"Husby S, Murray JA, Katzka DA. AGA clinical practice update on diagnosis and monitoring of celiac disease-changing utility of serology and histologic measures: expert review. Gastroenterology. 2019;156:885\u2013889.","journal-title":"Gastroenterology"},{"key":"6454_CR16","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/ajg.2016.439","volume":"111","author":"I Comino","year":"2016","unstructured":"Comino I, Fernandez-Banares F, Esteve M, et al. Fecal gluten peptides reveal limitations of serological tests and food questionnaires for monitoring gluten-free diet in celiac disease patients. Am J Gastroenterol. 2016;111:1456\u20131465.","journal-title":"Am J Gastroenterol"},{"key":"6454_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1136\/gutjnl-2015-310148","volume":"66","author":"ML Moreno","year":"2017","unstructured":"Moreno ML, Cebolla A, Munoz-Suano A, et al. Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing. Gut. 2017;66:250\u2013257.","journal-title":"Gut"},{"key":"6454_CR18","doi-asserted-by":"crossref","unstructured":"Silvester JA, Comino I, Kelly CP, Sousa C, Duerksen DR, DOGGIE BAG Study Group. Most patients with celiac disease on gluten-free diets consume measurable amounts of gluten. Gastroenterology. 2020;158:1497\u20131499.e1.","DOI":"10.1053\/j.gastro.2019.12.016"},{"key":"6454_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/MPG.0000000000001270","volume":"64","author":"D Gidrewicz","year":"2017","unstructured":"Gidrewicz D, Trevenen CL, Lyon M, Butzner JD. Normalization time of celiac serology in children on a gluten-free diet. J Pediatr Gastroenterol Nutr. 2017;64:362\u2013367.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"6454_CR20","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1080\/00365521.2016.1218540","volume":"51","author":"P Haere","year":"2016","unstructured":"Haere P, Hoie O, Schulz T, Schonhardt I, Raki M, Lundin KE. Long-term mucosal recovery and healing in celiac disease is the rule: not the exception. Scand J Gastroenterol. 2016;51:1439\u20131446.","journal-title":"Scand J Gastroenterol"},{"key":"6454_CR21","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/ajg.2015.155","volume":"110","author":"H Pekki","year":"2015","unstructured":"Pekki H, Kurppa K, Maki M, et al. Predictors and significance of incomplete mucosal recovery in celiac disease after 1\u00a0year on a gluten-free diet. Am J Gastroenterol. 2015;110:1078\u20131085.","journal-title":"Am J Gastroenterol"},{"key":"6454_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1177\/2050640619844125","volume":"7","author":"A Al-Toma","year":"2019","unstructured":"Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur Gastroenterol J. 2019;7:583\u2013613.","journal-title":"United Eur Gastroenterol J"},{"key":"6454_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1053\/j.gastro.2015.11.008","volume":"150","author":"GC Nguyen","year":"2016","unstructured":"Nguyen GC, Smalley WE, Vege SS, Carrasco-Labra A, Clinical Guidelines C. American Gastroenterological Association Institute guideline on the medical management of microscopic colitis. Gastroenterology. 2016;150:242\u2013246.","journal-title":"Gastroenterology"},{"key":"6454_CR24","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1016\/j.cgh.2017.12.044","volume":"16","author":"A Sharma","year":"2018","unstructured":"Sharma A, Choung RS, Wang XJ, et al. Features of adult autoimmune enteropathy compared with refractory celiac disease. Clin Gastroenterol Hepatol. 2018;16:e871.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6454_CR25","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.jaip.2019.01.053","volume":"7","author":"K Kennedy","year":"2019","unstructured":"Kennedy K, Muir AB, Grossman A, et al. Modified oral enteric-coated budesonide regimens to treat pediatric eosinophilic gastroenteritis, a single center experience. J Allergy Clin Immunol Pract. 2019;7:2059\u20132061.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"6454_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pupt.2016.07.001","volume":"40","author":"G Pelaia","year":"2016","unstructured":"Pelaia G, Vatrella A, Busceti MT, et al. Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma. Pulm Pharmacol Ther. 2016;40:15\u201321.","journal-title":"Pulm Pharmacol Ther"},{"key":"6454_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/MPG.0000000000001634","volume":"66","author":"N Sansotta","year":"2018","unstructured":"Sansotta N, Amirikian K, Guandalini S, Jericho H. Celiac disease symptom resolution: effectiveness of the gluten-free diet. J Pediatr Gastroenterol Nutr. 2018;66:48\u201352.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"6454_CR28","doi-asserted-by":"publisher","first-page":"e1551","DOI":"10.1016\/j.cgh.2017.02.016","volume":"15","author":"B Christensen","year":"2017","unstructured":"Christensen B, Hanauer SB, Erlich J, et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol. 2017;15:e1551.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06454-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06454-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06454-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T23:14:51Z","timestamp":1625958891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06454-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["6454"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06454-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,11]]},"assertion":[{"value":"9 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Not related to the current work; Daniel Leffler is employed by Takeda Pharmaceuticals International Co. Ciaran Kelly has acted as a scientific advisor to Cour Pharmaceuticals, Glutenostics, Innovate, ImmunogenX, and Takeda Pharmaceuticals. He has received research funding from Aptalis. Alessio Fasano is a stock owner of Alba Therapeutics, has received consulting fees by AbbVie, Innovate Biopharmaceuticals and uBiome, has a speaking agreement with Mead Johnson Nutritional and research agreement with Takeda. Maureen Leonard has received speaker fees from Takeda Pharmaceuticals, research funding from Glutenostics LLC and has received consulting fees from Healthmode and Anokion. Jocelyn A. Silvester has received consulting fees from Takeda Pharmaceuticals International Co, and research funding from Cour Pharmaceuticals, Biomedal SL, and Glutenostics LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}